Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Autologous KRAS mutant TCR-transduced PBLs |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
Autologous KRAS mutant TCR-transduced PBLs are peripheral blood lymphocytes engineered to express a T-cell receptor (TCR) specific for a KRAS mutation, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing mutant KRAS (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C204252 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Aldesleukin + Autologous KRAS mutant TCR-transduced PBLs | Aldesleukin Autologous KRAS mutant TCR-transduced PBLs | 0 | 1 |
| Autologous KRAS mutant TCR-transduced PBLs | Autologous KRAS mutant TCR-transduced PBLs | 0 | 0 |